Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:CGEMNASDAQ:ENTANASDAQ:ETON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$5.70-1.0%$5.10$3.55▼$11.16$438.98M1.132.85 million shs2.19 million shsCGEMCullinan Therapeutics$7.13-6.4%$8.05$6.85▼$28.11$420.78M-0.07589,549 shs427,179 shsENTAEnanta Pharmaceuticals$5.18-1.0%$5.59$4.09▼$17.24$110.51M0.81286,130 shs116,227 shsETONEton Pharmaceuticals$17.12+0.3%$14.60$3.18▼$20.96$459.12M1.22187,549 shs663,200 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-4.16%+14.51%+30.61%-7.40%-21.85%CGEMCullinan Therapeutics-3.67%-2.93%-1.17%-22.95%-70.84%ENTAEnanta Pharmaceuticals-5.77%+3.56%+11.51%-10.75%-59.49%ETONEton Pharmaceuticals-1.61%+2.86%+37.11%+0.53%+380.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.3128 of 5 stars3.51.00.00.02.03.30.6CGEMCullinan Therapeutics2.3612 of 5 stars3.52.00.00.02.12.50.6ENTAEnanta Pharmaceuticals3.6991 of 5 stars3.41.00.04.71.22.50.6ETONEton Pharmaceuticals2.6721 of 5 stars3.53.00.00.03.80.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$20.20254.39% UpsideCGEMCullinan Therapeutics 3.00Buy$32.00348.81% UpsideENTAEnanta Pharmaceuticals 2.80Moderate Buy$17.25233.01% UpsideETONEton Pharmaceuticals 3.00Buy$28.3365.50% UpsideCurrent Analyst Ratings BreakdownLatest ENTA, CGEM, ETON, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$26.00 ➝ $28.005/12/2025CGEMCullinan TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $24.004/16/2025CGEMCullinan TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.004/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/19/2025ETONEton PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.003/19/2025ETONEton PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $24.003/19/2025ETONEton PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/18/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/14/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/7/2025CGEMCullinan TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$38.00 ➝ $35.003/3/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K21,948.99N/AN/A$2.75 per share2.07CGEMCullinan TherapeuticsN/AN/AN/AN/A$10.61 per shareN/AENTAEnanta Pharmaceuticals$66.59M1.66N/AN/A$5.24 per share0.99ETONEton Pharmaceuticals$39.01M11.77$0.00 per share4,502.79$0.60 per share28.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.45M-$1.34N/AN/AN/A-199,076.92%-55.81%-50.60%N/ACGEMCullinan Therapeutics-$153.16M-$2.91N/AN/AN/AN/A-26.54%-25.32%N/AENTAEnanta Pharmaceuticals-$116.04M-$4.95N/AN/AN/A-157.57%-75.53%-27.30%N/AETONEton Pharmaceuticals-$940K-$0.15N/A34.24N/A-15.81%-36.29%-16.84%N/ALatest ENTA, CGEM, ETON, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025CGEMCullinan Therapeutics-$0.80N/AN/AN/AN/AN/A5/13/2025Q1 2025ETONEton Pharmaceuticals$0.05$0.07+$0.02-$0.06$14.33 million$17.28 million5/12/2025Q2 2025ENTAEnanta Pharmaceuticals-$1.04-$1.06-$0.02-$1.06$15.96 million$14.93 million5/8/2025Q1 2025ALTAltimmune-$0.36-$0.26+$0.10-$0.26$0.00 millionN/A5/8/2025Q1 2025CGEMCullinan Therapeutics-$0.78-$0.74+$0.04-$0.74N/AN/A3/18/2025Q4 2024ETONEton Pharmaceuticals-$0.02-$0.02N/A-$0.02$10.53 million$11.65 million2/27/2025Q4 2024ALTAltimmune-$0.34-$0.33+$0.01-$0.33$0.00 million$0.01 million2/27/2025Q4 2024CGEMCullinan Therapeutics-$0.75-$0.73+$0.02-$0.73N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/AENTAEnanta PharmaceuticalsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A16.8716.87CGEMCullinan TherapeuticsN/A24.4624.46ENTAEnanta PharmaceuticalsN/A5.475.47ETONEton PharmaceuticalsN/A1.511.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CGEMCullinan Therapeutics86.31%ENTAEnanta Pharmaceuticals94.99%ETONEton Pharmaceuticals27.86%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CGEMCullinan Therapeutics7.16%ENTAEnanta Pharmaceuticals13.89%ETONEton Pharmaceuticals16.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5077.01 million68.21 millionOptionableCGEMCullinan Therapeutics3059.02 million54.69 millionOptionableENTAEnanta Pharmaceuticals16021.33 million18.37 millionOptionableETONEton Pharmaceuticals2026.82 million22.17 millionOptionableENTA, CGEM, ETON, and ALT HeadlinesRecent News About These CompaniesEton Pharmaceuticals to Participate at Upcoming Investor ConferencesMay 14 at 4:30 PM | globenewswire.comA Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 AnalystsMay 14 at 2:55 PM | benzinga.comQ1 2025 Eton Pharmaceuticals Inc Earnings CallMay 14 at 9:54 AM | finance.yahoo.comEton outlines path to $100M near-term revenue with ET-400 launch and Increlex growthMay 13 at 11:52 PM | msn.comEton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call TranscriptMay 13 at 11:36 PM | seekingalpha.comEton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag EstimatesMay 13 at 6:20 PM | zacks.comEton Pharmaceuticals Reports First Quarter 2025 Financial ResultsMay 13 at 4:01 PM | globenewswire.comZevra Therapeutics's Earnings OutlookMay 12 at 7:01 PM | benzinga.comA Look Ahead: Eton Pharmaceuticals's Earnings ForecastMay 12 at 7:01 PM | benzinga.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Bought by Schonfeld Strategic Advisors LLCMay 10, 2025 | marketbeat.comEnvestnet Asset Management Inc. Invests $236,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 10, 2025 | marketbeat.comBarclays PLC Takes Position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 9, 2025 | marketbeat.com7EYPT : A Peek at EyePoint Pharmaceuticals's Future EarningsMay 6, 2025 | benzinga.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Marshall Wace LLPMay 5, 2025 | marketbeat.com683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 4, 2025 | marketbeat.comEton Pharmaceuticals (ETON) to Release Quarterly Earnings on ThursdayMay 3, 2025 | marketbeat.comQ1 EPS Estimate for Eton Pharmaceuticals Lifted by AnalystMay 2, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)May 2, 2025 | marketbeat.comEton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025May 1, 2025 | globenewswire.comEton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseMay 1, 2025 | zacks.comB. Riley Lifts Earnings Estimates for Eton PharmaceuticalsMay 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesFundamentally Sound, These 5 Stocks Sold Off AnywayBy Thomas Hughes | April 23, 2025View Fundamentally Sound, These 5 Stocks Sold Off Anyway3 Undervalued Stocks Wall Street Is Getting WrongBy Gabriel Osorio-Mazilli | May 12, 2025View 3 Undervalued Stocks Wall Street Is Getting Wrong3 Stocks To Watch For When Tariffs Subside By Gabriel Osorio-Mazilli | April 25, 2025View 3 Stocks To Watch For When Tariffs Subside Occidental’s Hidden Gem: How OxyChem Could Boost ProfitsBy Jea Yu | April 29, 2025View Occidental’s Hidden Gem: How OxyChem Could Boost Profits3 Boring Stocks Outperforming the Market This YearBy Ryan Hasson | April 25, 2025View 3 Boring Stocks Outperforming the Market This YearENTA, CGEM, ETON, and ALT Company DescriptionsAltimmune NASDAQ:ALT$5.70 -0.06 (-1.04%) As of 04:00 PM EasternAltimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cullinan Therapeutics NASDAQ:CGEM$7.13 -0.49 (-6.43%) As of 04:00 PM EasternCullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Enanta Pharmaceuticals NASDAQ:ENTA$5.18 -0.05 (-0.96%) As of 04:00 PM EasternEnanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$17.12 +0.05 (+0.29%) As of 04:00 PM EasternEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
